Pfizer has announced the voluntary withdrawal of all lots of OXBRYTA (voxelotor) approved for treating sickle cell disease ...

The pharmaceutical giant last week announced it would voluntarily withdraw its sickle cell disease therapy, Oxbryta, from ...

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

Oxbryta (voxelotor) is a brand-name drug that’s prescribed for sickle cell disease in adults and certain children. As with other drugs, Oxbryta can cause side effects, such as headache ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

Takeaway: The suit is the latest in a string of suits filed following the recall of Oxbryta, a drug used to treat sickle-cell disease. Lawyers: Marcus J. Bradley and Kiley Lynn Grombacher of ...

Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...

Recent Developments in Sickle Cell Disease Treatments Globally, the treatment for SCD continues to evolve, albeit the challenges. Voxelotor, a drug marketed as Oxbryta by Pfizer, was hailed as a ...